Donation

Myeloma Minute: Coronavirus Update

myelomaMinBannerTemplate11.21.19.jpg

| INNOVATION | Latest Research

540x270Coronavirus2.jpg

Coronavirus (COVID-19) Update: Elbows or Shoes, But No Handshakes!

Concern about safety for myeloma patients intensified this week as cases of coronavirus “community spread” increased in the U.S. IMF Chairman Dr. Brian G.M. Durie updates his guidelines for staying safe and healthy, and shares reports from around the world that shed light on the battle to contain this novel virus.

ReadBlogButton.png

| EDUCATION | Seminar

540x270BocaWebinar.jpg

IMF Patient & Family Seminar in Boca Raton, Florida, Now Hosted Online Instead of In Person

For 30 years, the paramount concern of the International Myeloma Foundation (IMF) has been the health and safety of patients and caregivers. With that duty in mind, and out of an abundance of caution, the IMF today announced that the organization’s 2020 Patient & Family Seminar, held annually in Boca Raton, Florida, will be presented online instead of in person on Saturday, March 14.

Please note for those who are already registered for the IMF Patient & Family Seminar in Boca Raton, FL, you will be automatically registered for the March 14 online webinar. You will receive an email on how to log on to the upcoming online webinar.

Due to the change of the Boca PFS from a physical meeting to a web-based meeting we are happy to:

  • Refund your registration fee.
  • Adjust your registration fee to be a donation.

Feel free to contact us at the IMF at 1-800-452-2873 if you would like either choice above.

For those anywhere in the country who have not registered and are interested in taking part in the March 14 online webinar, registration details are to come at the link below.

LearnMoreButton.png

| INSPIRATION | Patient Story

250x250DanNiedert.jpg

| ACTION | Join the Movement

250x250mamboxlogo.jpg

Read a Transcript of a Powerful Speech Given by Myeloma Patient Dan Niedert
March Opens with a Roar as Myeloma Action Month Takes Over Social Media

At the Brian D. Novis Research Grant Awards reception, a night filled with hope held during the 2019 American Society of Hematology meeting, Dan Niedert described his experiences of living with multiple myeloma. He shares how he enjoys a quality of life today that he did not expect at the time of diagnosis. Read a transcript of Dan’s speech from how he went from veiling his diagnosis in a “cloak of privacy,” to becoming an active IMF Support Group Leader.

As of March 1, the International Myeloma Foundation launched our resilience-themed Myeloma Action Month campaign. Members of the myeloma community and beyond have been challenged to share their images and stories on Facebook, Twitter, and Instagram with the hashtag #IAMRESILIENT2020. Your stories are now live at https://mam.myeloma.org/. Visit the site and explore all the ways you can take action this month to make an impact for the global myeloma community.

ReadNowButton.png

ButtonVisitNow.png

| INNOVATION | FDA Approval

540x270ResearchLab.jpg

International Myeloma Foundation Pleased to Announce FDA Approval of Sarclisa (isatuximab-irfc)

The International Myeloma Foundation is very pleased that Sarclisa (isatuximab-irfc), a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, has just been approved by the FDA. This approval means patients with relapsed/refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor have a new option. Dr. Brian G.M. Durie comments on this approval here, and read the full press release below.

LearnMoreButton.png

| INNOVATION | Clinical Trial

540x270clinicalTrialsbook.jpg

Phase III Boston Study Meets Its Primary Endpoint

The randomized phase III BOSTON study evaluates “once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one to three prior lines of therapy.” Karyopharm Therapeutics Inc. announced that “the BOSTON study met its primary endpoint of a statistically significant increase in progression-free survival (PFS).” Learn more at the link below.

LearnMoreButton.png

| INSPIRATION | IMF FUNraisers

540x270MFRevent.jpg

A Notice About IMF Member FUNraisers

During the month of March, the IMF has a number of Member FUNraisers scheduled. These volunteer-organized events raise funds for the International Myeloma Foundation in fun and engaging ways. With the recent outbreak of the coronavirus, the IMF encourages you to follow public health safety guidelines as outlined by the Centers for Disease Control, and your local county’s department of health. We are always here for your questions and concerns as well.

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox11.1.18.png

CLINICAL TRIALS
EVENTS

Search the Myeloma Matrix 2.0

Join the conversation about myeloma on the Smart Patients Message Board

Clinical Trial Fact Sheets

OCEAN Trial (Now Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Ongoing
Hawaiian Vacation Raffle
Kailua-Kona, Hawaii

March 7, 2020
Masters Tennis for Myeloma
Villages, FL

March 13-14, 2020
IMF Patient & Family Seminar
Boca Raton, FL

March 21, 2020
Walk for Myeloma Miracles
Rancho Cucamonga, CA

April 25, 2020
12th Annual Miles for Myeloma 5K Run/Walk
Philadelphia, PA

April 25, 2020
IMF Regional Community Workshop
Overland Park, KS

subscribe_button.png     donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Bristol-Myers Squibb, Genentech, Sanofi-Genzyme, and Takeda Oncology

We also thank individuals like you for your continued support!

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.